Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714646 | 0.98 | JAK2 (0.40) | JAK2JAK1MEN1KMT2AALDH1A1 | |
| SCHEMBL3600694 | 0.81 | CCR5 (0.40) | — | |
| SCHEMBL17856438 | 0.81 | GAA (0.36) | ALDH1A1MAPTALOX15TDP1GAA | |
| SCHEMBL3594511 | 0.80 | DPP4 (0.39) | JAK2JAK1HTR2CTP53BRD4 | |
| SCHEMBL16447914 | 0.79 | MEN1 (0.45) | JAK2JAK1MEN1KMT2AHTR2C | |
| SCHEMBL3607799 | 0.79 | JAK2 (0.33) | JAK2JAK1TP53BRD4CCR3 | |
| SCHEMBL5634958 | 0.77 | NSD3 (0.46) | JAK2JAK1KMT2AHTR2CCHRNB2 | |
| SCHEMBL20682653 | 0.77 | GAA (0.44) | JAK2JAK1MEN1KMT2AALDH1A1 | |
| SCHEMBL5634461 | 0.73 | CCR5 (0.48) | HTR2CTP53BRD4NSD3GABRA1 | |
| SCHEMBL5203169 | 0.71 | MAPT (0.46) | JAK2JAK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793596-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10138270-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9359399-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150197545-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-8951970-B2 | Synthetic peptide amides for pain | CARA THERAPEUTICS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8486894-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130012448-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2064228-B1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8217007-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7727963-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2064228-A2 | SYNTHETIC PEPTIDE AMIDES | Cara Therapeutics, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2008057608-A2 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138270-B2 | Synthetic peptide amides | VIP, OPRK1, OPRL1 | JAK2 1590/4885JAK1 726/4885MEN1 4740/4885 |
| US-20150197545-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | JAK2 1590/4885JAK1 726/4885MEN1 4740/4885 |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | OPRK1, OPRL1, OPRD1 | JAK2 2354/4885JAK1 1691/4885MEN1 4840/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | JAK2 1720/4885JAK1 961/4885MEN1 4818/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | JAK2 2197/4885JAK1 1098/4885MEN1 4795/4885 |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | JAK2 2197/4885JAK1 1098/4885MEN1 4795/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | JAK2 1590/4885JAK1 726/4885MEN1 4740/4885 |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | JAK2 1590/4885JAK1 726/4885MEN1 4740/4885 |
| US-20130012448-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | JAK2 1590/4885JAK1 726/4885MEN1 4740/4885 |
| US-10793596-B2 | Synthetic peptide amides | OPRK1, OPRL1, OPRD1 | JAK2 2354/4885JAK1 1691/4885MEN1 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.